Clinical Trial Update: Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT [NA]

View source ↗

Summary

A clinical trial evaluating treatment response in Non-Hodgkin lymphoma using Copper-64 labeled Rituximab PET/CT has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• 64Cu-DOTA-Rituximab PET/CT (Copper-64 labeled Rituximab)

Snippet

Sponsor: Sanjiv Sam Gambhir | Conditions: Non-Hodgkin's Lymphoma | NA | Status: WITHDRAWN